S&P 500   4,564.49 (+0.21%)
DOW   35,552.62 (+0.38%)
QQQ   390.90 (+0.18%)
AAPL   189.37 (-0.54%)
MSFT   379.23 (-0.91%)
META   332.81 (-1.82%)
GOOGL   135.34 (-1.36%)
AMZN   146.77 (-0.18%)
TSLA   246.22 (-0.20%)
NVDA   481.45 (+0.68%)
NIO   7.21 (+0.00%)
BABA   74.90 (-2.40%)
AMD   124.55 (+2.08%)
T   16.32 (+0.87%)
F   10.66 (+2.80%)
MU   76.80 (+0.89%)
CGC   0.57 (+4.89%)
GE   119.25 (+0.34%)
DIS   93.07 (+0.62%)
AMC   7.22 (+7.76%)
PFE   30.12 (+1.45%)
PYPL   58.41 (-0.10%)
XOM   103.63 (-0.26%)
S&P 500   4,564.49 (+0.21%)
DOW   35,552.62 (+0.38%)
QQQ   390.90 (+0.18%)
AAPL   189.37 (-0.54%)
MSFT   379.23 (-0.91%)
META   332.81 (-1.82%)
GOOGL   135.34 (-1.36%)
AMZN   146.77 (-0.18%)
TSLA   246.22 (-0.20%)
NVDA   481.45 (+0.68%)
NIO   7.21 (+0.00%)
BABA   74.90 (-2.40%)
AMD   124.55 (+2.08%)
T   16.32 (+0.87%)
F   10.66 (+2.80%)
MU   76.80 (+0.89%)
CGC   0.57 (+4.89%)
GE   119.25 (+0.34%)
DIS   93.07 (+0.62%)
AMC   7.22 (+7.76%)
PFE   30.12 (+1.45%)
PYPL   58.41 (-0.10%)
XOM   103.63 (-0.26%)
S&P 500   4,564.49 (+0.21%)
DOW   35,552.62 (+0.38%)
QQQ   390.90 (+0.18%)
AAPL   189.37 (-0.54%)
MSFT   379.23 (-0.91%)
META   332.81 (-1.82%)
GOOGL   135.34 (-1.36%)
AMZN   146.77 (-0.18%)
TSLA   246.22 (-0.20%)
NVDA   481.45 (+0.68%)
NIO   7.21 (+0.00%)
BABA   74.90 (-2.40%)
AMD   124.55 (+2.08%)
T   16.32 (+0.87%)
F   10.66 (+2.80%)
MU   76.80 (+0.89%)
CGC   0.57 (+4.89%)
GE   119.25 (+0.34%)
DIS   93.07 (+0.62%)
AMC   7.22 (+7.76%)
PFE   30.12 (+1.45%)
PYPL   58.41 (-0.10%)
XOM   103.63 (-0.26%)
S&P 500   4,564.49 (+0.21%)
DOW   35,552.62 (+0.38%)
QQQ   390.90 (+0.18%)
AAPL   189.37 (-0.54%)
MSFT   379.23 (-0.91%)
META   332.81 (-1.82%)
GOOGL   135.34 (-1.36%)
AMZN   146.77 (-0.18%)
TSLA   246.22 (-0.20%)
NVDA   481.45 (+0.68%)
NIO   7.21 (+0.00%)
BABA   74.90 (-2.40%)
AMD   124.55 (+2.08%)
T   16.32 (+0.87%)
F   10.66 (+2.80%)
MU   76.80 (+0.89%)
CGC   0.57 (+4.89%)
GE   119.25 (+0.34%)
DIS   93.07 (+0.62%)
AMC   7.22 (+7.76%)
PFE   30.12 (+1.45%)
PYPL   58.41 (-0.10%)
XOM   103.63 (-0.26%)

Trinity Biotech Stock Price, News & Analysis (NASDAQ:TRIB)

$0.44
+0.00 (+1.09%)
(As of 02:08 PM ET)
Compare
Today's Range
$0.42
$0.45
50-Day Range
$0.39
$0.74
52-Week Range
$0.37
$1.37
Volume
83,731 shs
Average Volume
41,015 shs
Market Capitalization
$16.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Trinity Biotech MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.16% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.37mentions of Trinity Biotech in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.59) to ($0.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.11 out of 5 stars

Medical Sector

928th out of 949 stocks

Diagnostic Substances Industry

14th out of 14 stocks


TRIB stock logo

About Trinity Biotech Stock (NASDAQ:TRIB)

Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

TRIB Stock Price History

TRIB Stock News Headlines

StockNews.com Begins Coverage on Trinity Biotech (NASDAQ:TRIB)
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
Trinity Biotech Announces Q2 2023 Financial Results
See More Headlines
Receive TRIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trinity Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/03/2023
Today
11/29/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TRIB
Employees
398
Year Founded
1992

Profitability

Net Income
$-41,010,000.00
Pretax Margin
-64.52%

Debt

Sales & Book Value

Annual Sales
$74.78 million
Book Value
($0.06) per share

Miscellaneous

Free Float
34,983,000
Market Cap
$16.70 million
Optionable
Optionable
Beta
1.44

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Aris Kekedjian (Age 56)
    CEO & Chairman
    Comp: $387k
  • Mr. Ronan O'Caoimh (Age 67)
    Founder & Director
    Comp: $340k
  • Mr. John Gillard (Age 42)
    CFO, Company Secretary & Executive Director
    Comp: $863k
  • Dr. James Walsh Ph.D. (Age 65)
    Executive Director of Business Development & Executive Director
    Comp: $20k
  • Mr. Simon Dunne (Age 49)
    Chief Accounting Officer
  • Dr. Gary Keating Ph.D. (Age 50)
    Chief Technology Officer
  • Ms. Eibhlin Kelly (Age 39)
    Chief Information Officer
  • Mr. Colm Molloy (Age 52)
    Group Director of Human Resources & Culture














TRIB Stock Analysis - Frequently Asked Questions

How have TRIB shares performed in 2023?

Trinity Biotech's stock was trading at $0.99 at the start of the year. Since then, TRIB shares have decreased by 55.7% and is now trading at $0.4382.
View the best growth stocks for 2023 here
.

Are investors shorting Trinity Biotech?

Trinity Biotech saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 59,700 shares, an increase of 70.1% from the October 31st total of 35,100 shares. Based on an average daily volume of 27,600 shares, the short-interest ratio is presently 2.2 days.
View Trinity Biotech's Short Interest
.

How were Trinity Biotech's earnings last quarter?

Trinity Biotech plc (NASDAQ:TRIB) released its quarterly earnings results on Tuesday, October, 3rd. The company reported ($0.20) EPS for the quarter. The business earned $13.90 million during the quarter. Trinity Biotech had a negative net margin of 46.51% and a negative trailing twelve-month return on equity of 870.11%.

What guidance has Trinity Biotech issued on next quarter's earnings?

Trinity Biotech issued an update on its third quarter 2023 earnings guidance on Tuesday, October, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $14.00 million-$15.00 million, compared to the consensus revenue estimate of $15.00 million.

What is Ronan O'Caoimh's approval rating as Trinity Biotech's CEO?

20 employees have rated Trinity Biotech Chief Executive Officer Ronan O'Caoimh on Glassdoor.com. Ronan O'Caoimh has an approval rating of 8% among the company's employees. This puts Ronan O'Caoimh in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Trinity Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trinity Biotech investors own include Gilead Sciences (GILD), Novavax (NVAX), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Netflix (NFLX), Pfizer (PFE), QUALCOMM (QCOM), Energy Transfer (ET) and Exxon Mobil (XOM).

Who are Trinity Biotech's major shareholders?

Trinity Biotech's stock is owned by a variety of retail and institutional investors. Top institutional investors include Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Trinity Biotech?

Shares of TRIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TRIB) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -